PT  - JOURNAL ARTICLE
AU  - Al-Mufti, F.
AU  - Amuluru, K.
AU  - Sahni, R.
AU  - Bekelis, K.
AU  - Karimi, R.
AU  - Ogulnick, J.
AU  - Cooper, J.
AU  - Overby, P.
AU  - Nuoman, R.
AU  - Tiwari, A.
AU  - Berekashvili, K.
AU  - Dangayach, N.
AU  - Liang, J.
AU  - Gupta, G.
AU  - Khandelwal, P.
AU  - Dominguez, J.F.
AU  - Sursal, T.
AU  - Kamal, H.
AU  - Dakay, K.
AU  - Taylor, B.
AU  - Gulko, E.
AU  - El-Ghanem, M.
AU  - Mayer, S.A.
AU  - Gandhi, C.
TI  - Cerebral Venous Thrombosis in COVID-19: A New York Metropolitan Cohort Study
AID  - 10.3174/ajnr.A7134
DP  - 2021 Apr 22
TA  - American Journal of Neuroradiology
4099  - http://www.ajnr.org/content/early/2021/04/22/ajnr.A7134.short
4100  - http://www.ajnr.org/content/early/2021/04/22/ajnr.A7134.full
AB  - BACKGROUND AND PURPOSE: Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is associated with hypercoagulability. We sought to evaluate the demographic and clinical characteristics of cerebral venous thrombosis among patients hospitalized for coronavirus disease 2019 (COVID-19) at 6 tertiary care centers in the New York City metropolitan area.MATERIALS AND METHODS: We conducted a retrospective multicenter cohort study of 13,500 consecutive patients with COVID-19 who were hospitalized between March 1 and May 30, 2020.RESULTS: Of 13,500 patients with COVID-19, twelve had imaging-proved cerebral venous thrombosis with an incidence of 8.8 per 10,000 during 3 months, which is considerably higher than the reported incidence of cerebral venous thrombosis in the general population of 5 per million annually. There was a male preponderance (8 men, 4 women) and an average age of 49 years (95% CI, 36–62 years; range, 17–95 years). Only 1 patient (8%) had a history of thromboembolic disease. Neurologic symptoms secondary to cerebral venous thrombosis occurred within 24 hours of the onset of the respiratory and constitutional symptoms in 58% of cases, and 75% had venous infarction, hemorrhage, or both on brain imaging. Management consisted of anticoagulation, endovascular thrombectomy, and surgical hematoma evacuation. The mortality rate was 25%.CONCLUSIONS: Early evidence suggests a higher-than-expected frequency of cerebral venous thrombosis among patients hospitalized for COVID-19. Cerebral venous thrombosis should be included in the differential diagnosis of neurologic syndromes associated with SARS-CoV-2 infection.COVID-19coronavirus disease 2019CVSTcerebral venous sinus thrombosisCVTcerebral venous thrombosisSARS-CoV-2Severe Acute Respiratory Syndrome coronavirus 2